Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female participants must be postmenopausal (after the time in life when a woman stops having a menstrual period) or surgically sterile or if sexually active, practicing an effective method of birth control (e.g., oral contraceptive, intrauterine device \[IUD - an intrauterine device made of plastic and/or copper that is inserted into the womb \[uterus\] by way of the vaginal canal to used to prevent pregnancy\], diaphragm with spermicide \[agent that kills spermatozoa\] or condom \[cover worn over the penis during sexual intercourse to prevent infection or pregnancy\] with spermicide) throughout the study and have a negative serum beta - Human Chorionic Gonadotropin (HCG) pregnancy test at screening~* Participants on oral monotherapy (treatment with a single drug) with risperidone in a regimen within the daily dosage recommended by the package insert and adhering to the prescribed risperidone regimen for at least 30 days before entering the study~* Participants with partial response to the current risperidone regimen (persistent symptoms or unstable clinical condition) or presence of unbearable side effects~* Potential Participants switching to another atypical antipsychotic due to their clinical response and/or side effects profile.~Exclusion Criteria:~* Participants with past or current history of psychiatric disease other than schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV~* Participants with concomitant (given at the same time) severe (very serious, life threatening) medical or neurological disorder or risk of suicide~* Participants previously using clozapine~* Participants with a history of previous non-responsiveness to oral antipsychotic treatment~* Pregnant or breast-feeding female participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Paliperidone Extended Release (ER) (Type: EXPERIMENTAL): Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).